Navigation Links
Questcor Pharmaceuticals Announces Preliminary Operating Metrics for Third Quarter 2011
Date:9/28/2011

ANAHEIM, Calif., Sept. 28, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced preliminary operating metrics for its third quarter ending September 30, 2011. The Company announced the estimated metrics in conjunction with the Jeffries Global Healthcare Conference in London, where Don M. Bailey, President and Chief Executive Officer of Questcor, presented on Wednesday, September 28, 2011, at 8:00 a.m. BT, 3:00 a.m. ET.  To listen to the audio web cast of the presentation, please visit www.questcor.com.  The replay will be available for 90 days after the event.

For the quarter ending September 30, 2011, the Company provided the following preliminary estimated operating metrics:

  • Based on internal Company data through September 26, 2011:
    • New, paid prescriptions of the Company's principal drug, H.P. Acthar® Gel (Acthar), for the treatment of exacerbations of multiple sclerosis (MS) during the full third quarter are expected to exceed 850, up over 160% from the year ago period.
    • New, paid prescriptions for nephrotic syndrome (NS) are expected to exceed 55.  
    • New, paid prescriptions for infantile spasms (IS) are expected to exceed 105.
  • Vials of Acthar, shipped during the quarter are expected to exceed 2,750, up over 45% from the year ago period.

During the third quarter, the Company has not repurchased any of its common stock. Prior repurchases have used over $78 million since this effort began in 2008.  As of September 26, 2011, Questcor had 62.7 million shares of common stock outstanding, with 4.3 million shares remaining under its common stock repurchase program.

As of September 26, 2011, Questcor's cash, cash equivalents and short-term
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on September 28, 2011
2. Questcor Provides Updated New Paid Prescription Trends
3. UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
4. Questcor Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 11, 2011
5. Questcor to Report Second Quarter 2011 Earnings and Conduct Conference Call on July 26, 2011
6. Questcor Proxy Proposals All Approved at 2011 Shareholder Meeting
7. Questcor Discusses ISS Proxy Recommendations; Provides Business Update
8. Questcor to Report First Quarter 2011 Earnings and Conduct Conference Call on April 26, 2011
9. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011
10. Questcor Pharmaceuticals to Present at the Needham Healthcare Conference
11. Questcor Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014   Surefire Medical ... infusion systems designed to maximize targeted delivery of embolization ... to announce that oncologist John R. Daniels , ... Cancer Center, and surgical oncologist Steven C. Katz ... joined the Company,s Scientific Advisory Board (SAB).    ...
(Date:10/22/2014)... AUSTIN, Texas , Oct. 22, ... today announced they have entered into a license ... designed to target cancers. PhosImmune possesses ... on the surfaces of tumor cells in association ... derived from proteins that play a role in ...
(Date:10/22/2014)... LA JOLLA, Calif. , Oct. 22, ... RGLS ), a biopharmaceutical company leading ... targeting microRNAs, today announced that it has ... from an ongoing clinical study evaluating RG-101, ... for the treatment of hepatitis C virus ...
Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
(Date:10/22/2014)... October 22, 2014 Although there are only 24 ... for many people who have trouble finding time within their busy ... exercise for long periods of time to get in shape. Here ... while on the go. , Change Up Your Commute , ... work to add some exercise into your daily routine. If you ...
(Date:10/22/2014)... Steven Reinberg HealthDay Reporter ... quickly add weight and length may be showing a genetic ... In adults, certain genes have been linked to increased body ... in fat and lean muscle, the researchers said. At ... taller. By ages 2 and 3, however, these genes were ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... part of conventional in vitro fertilization (IVF) -- the incubation ... place in a device inside the vagina, new research suggests. ... the device, called an INVOcell, might sharply cut costs for ... the technology more accessible to those who don,t live near ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 The newly ... must-have source of thousands of facts, figures and forecasts ... and 68 medical sector forecast categories the Worldwide ... global, regional and national views on the worldwide medical ... , The report gives you data for 2010-2019, covering ...
(Date:10/20/2014)... October 20, 2014 ASCNYC (ascnyc.org) ... that helps New Yorkers living with HIV/AIDS and ... health, housing, recovery and self-sufficiency. Each year, ASCNYC ... local community through their tireless efforts. , ... Shapses , has been selected as this year’s ...
Breaking Medicine News(10 mins):Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... can worsen the impact of asthma and may also mask ... Zealand, who studied lung function in asthmatic women with a ... first prospective study to reveal a significant comparative difference in ... attack in obese and non-obese individuals. , The research ...
... Trust, Inc.,(NYSE: BMR ), a real estate investment trust focused ... results for,the first quarter ended March 31, 2008., Highlights:, ... million, or $0.46 per diluted share, ... share, equivalent to an annualized common stock ...
... Brookdale Senior,Living Inc. (NYSE: BKD ) announced ... financial results after the market closes on Wednesday, May ... discuss the results on,Thursday, May 8, 2008 at 8:00 ... (866) 845-7252 (from within the U.S.) or (706) 634-9069 ...
... 30 New data is showing a dramatic,reduction ... in this country.,Here,s more on one group,s 20-year ... to this report from Safe Kids Worldwide at:, ... audio, text, graphics and,photos for free and unrestricted ...
... eligible Medicaid members, PHOENIX, April 30 ... law, allowing the state Medicaid program to,expend moneys ... Introduced by Sen. Barbara Leff (R-Paradise Valley), ... state,s General Fund and will provide benefits,for nicotine ...
... in relapsing remitting illness , , WEDNESDAY, April 30 (HealthDay ... people with the relapsing remitting form of multiple sclerosis ... the disease were randomly selected to receive either 20 ... for 24 weeks. MRI brain scans were conducted every ...
Cached Medicine News:Health News:Obesity worsens impact of asthma 2Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 2Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 3Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 4Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 5Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 6Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 7Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 8Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 9Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 10Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 11Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 12Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 13Health News:Brookdale Announces First Quarter 2008 Release and Earnings Call 2Health News:Governor Napolitano Signs Smoking Cessation Bill 2Health News:Prozac Reduces Disease Activity in MS Patients 2
Fine abrasive for knife sharpening, 6 grams net...
Knife sharpening back for Standard Knife, C Profile...
Standard knife with box, C profile...
... stage is a refrigerated design for use as ... use with the 8000 sledge microtome, however, it ... refrigerated stage gives a large working area of ... to provide good adhesion between the specimen and ...
Medicine Products: